Medical Oncology, Hospital San Juan de Dios, San José, Costa Rica; Centro de Investigación y Manejo del Cancer - CIMCA, San José, Costa Rica.
Thoracic Oncology Unit and Laboratory of Personalized Medicine, Instituto Nacional de Cancerología (INCan), México City, Mexico.
Lung Cancer. 2017 Nov;113:30-36. doi: 10.1016/j.lungcan.2017.08.022. Epub 2017 Sep 11.
A proportion of patients with NSCLC is diagnosed at 40 years or younger. These patients tend to be never-smokers, usually present with stage IV adenocarcinoma, and have somatic genomic alterations. Few studies have documented and analyzed epidemiological characteristics of this population.
We performed an international epidemiological analysis of 389 young patients with NSCLC. Data was collected from centers participating in the Latin American Consortium for Lung Cancer Research (AduJov-CLICaP). Patients were identified and data was retrospectively collected from different Latin American countries and Canada (Argentina=6, Canada=19, Colombia=29, Costa Rica=9, Mexico=219, Nicaragua=2, Panama=19, Perú=76 and Venezuela=10). The period of study was from 2012 to 2017. Inclusion criteria were: age 40 years or less and a histologically confirmed NSCLC. Clinical data was obtained, and EGFR mutation status and EML4-ALK translocation were collected.
NSCLC patients aged 40 years or less accounted for approximately 4% of the total NSCLC population. Female patients accounted for 54.5%, while median age was of 37 years. Adenocarcinoma accounted for 86.1% (n=335/389), 72.5% (n=282/389; unknown=5) of patients were non-smokers, and 90.3% (n=351/389) had stage IV disease. Site of metastasis was obtained from 260/351 (unknown=91) stage IV patients (lung metastasis=40.0%, CNS metastasis=35.7%, and bone metastasis=31.5%). OS for the total population was 17.3 months (95%CI=13.9-20.7). OS for EGFRm(+)=31.4months (95%CI=11.6-51.3), EGFRm(-)=14.5months (95%CI=11.0-17.9) (p=0.005). OS for alk(+)=9.8months (95%CI=3.1-16.5) and alk(-)=5.6months (95%CI=3.9-7.3) (p=0.315).
Patients aged 40 years or less account for a small but important proportion of NSCLC cases. Younger patients may have different characteristics compared to the older population. EGFRm and EML4-alk translocation frequency is higher than that of the general population.
一部分非小细胞肺癌(NSCLC)患者在 40 岁或更年轻时被诊断出患有这种疾病。这些患者往往从不吸烟,通常表现为 IV 期腺癌,并存在体细胞基因组改变。很少有研究记录和分析这一人群的流行病学特征。
我们对 389 名患有 NSCLC 的年轻患者进行了国际流行病学分析。数据来自参与拉丁美洲肺癌研究联盟(AduJov-CLICaP)的中心收集。从不同的拉丁美洲国家和加拿大确定并回顾性收集了患者的数据(阿根廷=6、加拿大=19、哥伦比亚=29、哥斯达黎加=9、墨西哥=219、尼加拉瓜=2、巴拿马=19、秘鲁=76 和委内瑞拉=10)。研究期间为 2012 年至 2017 年。纳入标准为:年龄 40 岁或以下,组织学证实为 NSCLC。收集临床数据,以及 EGFR 突变状态和 EML4-ALK 易位情况。
年龄在 40 岁或以下的 NSCLC 患者占 NSCLC 总患者的 4%左右。女性患者占 54.5%,中位年龄为 37 岁。腺癌占 86.1%(n=335/389),72.5%(n=282/389;未知=5)的患者不吸烟,90.3%(n=351/389)患有 IV 期疾病。从 260/351 名(未知=91)IV 期患者中获得了转移部位的信息(肺转移=40.0%,中枢神经系统转移=35.7%,骨转移=31.5%)。总人群的 OS 为 17.3 个月(95%CI=13.9-20.7)。EGFRm(+)的 OS 为 31.4 个月(95%CI=11.6-51.3),EGFRm(-)的 OS 为 14.5 个月(95%CI=11.0-17.9)(p=0.005)。alk(+)的 OS 为 9.8 个月(95%CI=3.1-16.5),alk(-)的 OS 为 5.6 个月(95%CI=3.9-7.3)(p=0.315)。
40 岁或以下的患者占 NSCLC 病例的一小部分,但却是很重要的一部分。年轻患者可能与老年患者有不同的特征。EGFRm 和 EML4-alk 易位的频率高于一般人群。